Sentence examples for stage efficacy from inspiring English sources

We describe evidence of vaccine-induced blood stage efficacy for the first time in a sporozoite challenge study.

Several vaccine candidates have previously provided evidence of pre-erythrocytic stage efficacy in phase IIa trials [8], [30], [31], [32].

In the absence of a group receiving only the PkMSP1 and PkAMA1 vaccines, we do know if the two pre-erythrocytic stage antigens contribute to this blood stage efficacy, or if protection against blood stage infections would be seen with a vaccine containing only PkMSP1 and PkAMA1.

However when the above compounds were applied at three or more growth stages efficacy as scab protectants was confirmed.

We are fully aware that any findings using rodent parasites require validation with respect to human malaria parasites; however, early-stage efficacy trials of this type using human volunteers are currently technically and ethically impossible (13).

CD8+ T cell responses were detected only against MSP-133, and their ability to mediate liver-stage protection is consistent with the expression of MSP-1 during liver-stage infection (Sacci et al., 2005) and a previous MSP-1 study that demonstrated comparable liver-stage efficacy (Kawabata et al., 2002) using a T cell-inducing vaccine technology that required intravenous vaccine administration.

The spz clinical challenge model allows for an assessment of complete or partial protection at the liver stage in immunized volunteers, and although blood-film positivity requires drug cure, partial blood-stage efficacy can be observed prior to this in partially protected volunteers by using real-time PCR (Thompson et al., 2008).

However, unlike protein vaccines, the concomitant induction of MSP-133-specific T cells and, to a lesser extent, antigen-nonspecific vector-induced responses can provide partial liver-stage efficacy in this mouse model and should allow for combination with similar partially effective pre-erythrocytic antigen vectors (Hill, 2006).

We intend to develop our vaccine candidates through the Phase 2 efficacy stage and then are likely to hand off late stage development and commercialization to a company with far greater resources than NovaDigm has access to.

Further data will be required to assess the utility and sensitivity of this assay for predicting blood stage vaccine efficacy, but these trial results suggest caution in the exclusive use of this assay as an in vitro predictor of blood-stage vaccine efficacy.

For stage I, efficacy analyses included all randomized patients, and safety analyses comprised the treated population.